Skip to main content
. 2020 Jul;9(7):4111–4120. doi: 10.21037/tcr-20-1451

Table 6. Clinical response according to LMR-week 6 for renal cell carcinoma patients.

Response Number (N=25, %) Low LMR-week 6 (N=15, 60%) High LMR-week 6 (N=10, 40%)
CR 4 (16.0) 1 (6.7) 3 (30.0)
PR 4 (16.0) 1 (6.7) 3 (30.0)
SD 8 (32.0) 7 (46.6) 1 (10.0)
PD 9 (36.0) 6 (40.0) 3 (30.0)

N, number; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; LMR-week 6, lymphocyte-to-monocyte ratio 6 weeks after the start of PD-1 inhibitors.